Dharti Proteins: Oct 13 board meet for bonus, Q2FY27

What the company has scheduled for October 13

Dharti Proteins Ltd (BSE: 531171) has informed the market that its Board of Directors will meet on Tuesday, October 13, 2026. The agenda includes approval of the audited standalone financial results for the second quarter and half year ended September 30, 2026. The meeting will also consider a proposal to issue bonus shares to public shareholders. The company’s intimation was filed with BSE Limited under Regulation 29 of the SEBI (LODR) Regulations, 2015.

The board meeting is positioned as a combined event covering both financial disclosure and a corporate action. While the intent of the bonus issue is stated, key specifics such as the bonus ratio and the post-issue capital structure are not disclosed in the preliminary notice. Investors typically wait for the outcome of the board meeting for the detailed terms and timelines, including record date and eligibility.

Why the bonus issue is being considered

The company has indicated that the proposed bonus shares are aimed at meeting Minimum Public Shareholding (MPS) requirements. The stated compliance objective is under Rule 19A of the Securities Contracts (Regulation) Rules, 1957, read with Regulation 38 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In simple terms, the company is linking the corporate action to the regulatory requirement on public shareholding levels.

A bonus share issue, as commonly understood, is a free share issued to existing shareholders based on their current holdings. The provided explanation also notes that a bonus increases the number of shares outstanding but does not change the company’s market capitalization by itself. Any market price adjustment after a bonus depends on how the stock trades, but the structural point is that the share count increases.

Stock move that drew attention

Dharti Proteins’ share price saw an unusually sharp move on BSE when it closed at ₹63.74 compared with a previous closing price of ₹3.45. This represented a rise of 1,747.54% versus the prior close, a gain of ₹60.29 per share in absolute terms.

Separately, the corporate action page also showed an LTP of ₹66.92, up 4.99% on October 13. These prices reflect different reference points shown in the provided information, but together they indicate heightened interest and volatility around the stock during the period when trading resumed and the board meeting was approaching.

What triggered the sudden spike

As per the provided details, the stock became available for trading again on BSE from October 8, 2026. The trading has been in the XT group, and the stock has been placed in the Trade-to-Trade segment.

Trade-to-Trade classification typically means trades must result in delivery and cannot be treated like normal intraday transactions. This framework can change the trading behaviour in the stock because speculative intraday churn is restricted and settlement is delivery-based. The resumption of trading, combined with the segment classification, forms the stated backdrop to the sharp move.

What will be approved in the results item

The board meeting agenda includes consideration and approval of audited standalone financial results for Q2FY27 and H1FY27. It also includes taking on record the interim audit report, as stated in the agenda highlights.

The board meeting is described as the company’s fourth Board Meeting of FY27. For investors tracking small listed companies, the audited half-year numbers often provide a clearer picture than a single quarter, especially when operations or income patterns are irregular.

Recent financial snapshot already on record (Q1FY27)

The available financial snapshot for the quarter ended June 30, 2026 (Q1FY27) indicates revenue from operations remained nil. The company reported a net loss of ₹0.1428 crore (₹14.28 lakh) for Q1FY27, widening from a loss of ₹0.0460 crore (₹4.60 lakh) in the prior year period. Total expenses rose to ₹0.1434 crore (₹14.34 lakh) from ₹0.0689 crore (₹6.89 lakh) in the prior year quarter, while other income fell to ₹0.0006 crore (₹0.06 lakh).

The unaudited standalone results for Q1FY27 were approved by the Board at a meeting held on July 15, 2026, and the statutory auditors issued an unmodified opinion. Separately, the company page also lists Revenue at ₹0.00 crore and Net Profit at ₹0.14 crore as on June 2026 (Q1 FY27), which aligns directionally with the quarter’s low activity and small absolute profit or loss figures shown in the provided material.

Other corporate context: AGM and funding resolution

The FY26 annual report dated September 28, 2026 states that the board comprises six directors, including four independent directors. It also notes that no dividend was proposed due to losses.

The AGM-related information also references a resolution for a convertible loan. Specifically, it mentions approval for an unsecured loan of up to ₹100 crore from Managing Director Jatinbhai Ramanbhai Patel, with an option to convert outstanding principal and/or interest into equity shares later, subject to SEBI guidelines. This item is separate from the October 13 board agenda in the provided text, but it adds context to the company’s broader corporate actions and capital planning during FY27.

Key dates investors are watching

The provided events list includes an earnings release entry dated October 13, 2026 for Q2 2027 earnings release. It also lists Q3 2027 earnings release on March 24, 2027, and Q4 2027 earnings release on May 28, 2027. The company’s “Upcoming Events” section also shows the next results date as 13/10/2026.

Below is a consolidated table of the key factual markers available from the provided information.

Market impact: what is known, and what is still pending

The immediate market impact in the provided material is the sharp price adjustment after trading resumed, followed by attention around the upcoming board meeting. The Trade-to-Trade classification is also relevant because it changes how liquidity and turnover behave in the stock by requiring delivery-based settlement.

On the corporate action side, the bonus issue proposal is tied to Minimum Public Shareholding compliance, but investors do not yet have the ratio, record date, or ex-bonus date from the preliminary notice. Those details, if approved, typically come through subsequent exchange disclosures after the board meeting.

Business profile in brief

Dharti Proteins Ltd is engaged in processing and marketing of edible, non-edible, and castor oils. The company was founded on June 6, 1994 and is headquartered in Ahmedabad, India.

This business description provides the operating context, while the recent financial disclosures point to very limited operating revenue in Q1FY27. The October 13 board meeting is therefore an important near-term event for both updated audited numbers and clarity on the proposed bonus issue.

Conclusion

Dharti Proteins’ board will meet on October 13, 2026 to approve audited standalone results for Q2FY27 and H1FY27 and to consider a bonus issue aimed at Minimum Public Shareholding compliance. The stock has also been in focus after resuming trading on BSE from October 8, 2026 in the XT group and Trade-to-Trade segment. The next concrete updates are expected through the board’s outcome disclosures, including the audited financial results and any specific terms of the proposed bonus issue.